Cargando…
Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines
BACKGROUND: YM529 is a newly developed nitrogen-containing bisphosphonate (BP) classified as a third-generation BP that shows a 100-fold greater potency against bone resorption than pamidronate, a second-generation BP. This agent is, therefore expected to be extremely useful clinically for the treat...
Autores principales: | Koshimune, Ryuichiro, Aoe, Motoi, Toyooka, Shinichi, Hara, Fumikata, Ouchida, Mamoru, Tokumo, Masaki, Sano, Yoshifumi, Date, Hiroshi, Shimizu, Nobuyoshi |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781945/ https://www.ncbi.nlm.nih.gov/pubmed/17222343 http://dx.doi.org/10.1186/1471-2407-7-8 |
Ejemplares similares
-
Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma
por: Kurabayashi, Atsushi, et al.
Publicado: (2015) -
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo
por: Sato, K, et al.
Publicado: (2006) -
Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non–small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701
por: Soh, Junichi, et al.
Publicado: (2016) -
Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice.
por: Nemoto, R., et al.
Publicado: (1993) -
The relationship between aberrant methylation and survival in non-small-cell lung cancers
por: Toyooka, S, et al.
Publicado: (2004)